Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial.

International Immunopharmacology
Payam TabarsiFarzaneh Dastan

Abstract

The newly discovered coronavirus has turned into coronavirus disease 2019 (COVID-19) pandemic and it rages at an unprecedented rate. Considering the findings of previous studies on the use of Intravenous Immunoglobulin (IVIg) for treating severe H1N1 infection and the satisfying results for reducing viral load and mortality, this study aimed to investigate the potential usefulness of IVIg for the management of severe cases. In this randomized controlled trial, 84 patients were included: 52 in the IVIg group and 32 in the control group. The intervention group received IVIg at a dose of 400 mg/kg, IV, daily for three days. Both groups received hydroxychloroquine, lopinavir/ritonavir and supportive care. The demographic data, mortality rate, the need for mechanical ventilation, length of stay in hospital and in Intensive Care Unit (ICU), and imaging findings were recorded and compared in terms of the mentioned factors. The mean time from admission to IVIg initiation was 3.84 ± 3.35 days. There was no significant difference between the two groups in terms of mortality rate (P-value = 0.8) and the need for mechanical ventilation (P-value = 0.39). The length of hospital stay was significantly lower for the control group than that of ...Continue Reading

References

Sep 20, 2008·Journal of Neurology·Hans-Peter Hartung
Feb 8, 2020·JAMA : the Journal of the American Medical Association·Dawei WangZhiyong Peng
Feb 29, 2020·The New England Journal of Medicine·Wei-Jie GuanUNKNOWN China Medical Treatment Expert Group for Covid-19
Apr 1, 2020·International Journal of Biological Sciences·Jun Zheng
Apr 3, 2020·The Lancet Infectious Diseases·Robert VerityNeil M Ferguson
May 19, 2020·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Alan A NguyenDouglas R McDonald

❮ Previous
Next ❯

Citations

Jun 9, 2021·Journal of Clinical Immunology·Donald C VinhUNKNOWN COVID Human Genetic Effort
Jul 16, 2021·SAGE Open Medical Case Reports·Carlos A Flores-OriaRicardo A Mosquera
Jul 9, 2021·Signal Transduction and Targeted Therapy·Lan YangYufeng Zhou
Jul 30, 2021·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Francisco López-Medrano, José María Aguado
Aug 3, 2021·Current Opinion in Critical Care·Xavier WitteboleJean-Baptiste Mesland
Sep 25, 2021·BMJ : British Medical Journal·Reed Ac SiemieniukRomina Brignardello-Petersen
Oct 11, 2021·Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology·Zahra KolahchiNima Rezaei
Oct 16, 2021·Frontiers in Public Health·Chenyang ZhangGuosheng Yin

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT04411667
NCT04261426

Software Mentioned

SPSS

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.